Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden
BACKGROUND: Chlamydia trachomatis salpingitis causes inflammatory damage to the fallopian tube and could potentially cause initiation and progression of high-grade serous ovarian cancer (HGSC). Furthermore, C. trachomatis infection may stimulate mucin 1 (MUC1) protein production, possibly affecting...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523319302992 |
id |
doaj-238636a82bcd4ee4968de363602f7c1d |
---|---|
record_format |
Article |
spelling |
doaj-238636a82bcd4ee4968de363602f7c1d2020-11-25T02:12:22ZengElsevierTranslational Oncology1936-52332020-01-011318691Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern SwedenSarah Jonsson0Eva Lundin1Fredrik Elgh2Ulrika Ottander3Annika Idahl4Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, 901 87, Sweden; Address all correspondence to: Sarah Jonsson, Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, 901 87, Sweden.Department of Medical Biosciences, Pathology, Umeå University, Umeå, 901 87, SwedenDepartment of Clinical Microbiology, Umeå University, Umeå, 901 87, SwedenDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, 901 87, SwedenDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, 901 87, SwedenBACKGROUND: Chlamydia trachomatis salpingitis causes inflammatory damage to the fallopian tube and could potentially cause initiation and progression of high-grade serous ovarian cancer (HGSC). Furthermore, C. trachomatis infection may stimulate mucin 1 (MUC1) protein production, possibly affecting anti-MUC1 antibody levels. The aim of this study was to examine if serology indicating past infection with C. trachomatis as well as anti-MUC1 production was associated with subsequent risk of HGSC. MATERIALS AND METHODS: In a prospective nested case–control study within the Northern Sweden Health and Disease Study and the Northern Sweden Maternity Cohort, the prevalence of chlamydial and anti-MUC1 antibodies was analyzed in blood samples drawn more than one year before diagnosis from 92 women with HGSC and 359 matched controls. Matching factors were age, date at blood draw, and sampling cohort. Plasma C. trachomatis IgG was analyzed using commercial micro-immunofluorescence test; chlamydial Heat Shock Protein 60 IgG (cHSP60) and anti-MUC1 IgG were analyzed with ELISA technique. RESULTS: The prevalence of C. trachomatis IgG and cHSP60 IgG antibodies, as well as the level of anti-MUC1 IgG was similar in women with HGSC and controls (16.3% vs. 17.0%, P = 0.87; 27.2% vs. 28.5%, P = 0.80; median 0.24 vs. 0.25, P = 0.70). Anti-MUC1 IgG and cHSP60 IgG levels were correlated (r = 0.169; P < 0.001). CONCLUSIONS: The findings of this prospective nested case–control study did not support an association between C. trachomatis infection, as measured by chlamydial serology, or anti-MUC1 IgG antibodies, and subsequent risk of HGSC.http://www.sciencedirect.com/science/article/pii/S1936523319302992 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sarah Jonsson Eva Lundin Fredrik Elgh Ulrika Ottander Annika Idahl |
spellingShingle |
Sarah Jonsson Eva Lundin Fredrik Elgh Ulrika Ottander Annika Idahl Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden Translational Oncology |
author_facet |
Sarah Jonsson Eva Lundin Fredrik Elgh Ulrika Ottander Annika Idahl |
author_sort |
Sarah Jonsson |
title |
Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden |
title_short |
Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden |
title_full |
Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden |
title_fullStr |
Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden |
title_full_unstemmed |
Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden |
title_sort |
chlamydia trachomatis and anti-muc1 serology and subsequent risk of high-grade serous ovarian cancer: a population-based case–control study in northern sweden |
publisher |
Elsevier |
series |
Translational Oncology |
issn |
1936-5233 |
publishDate |
2020-01-01 |
description |
BACKGROUND: Chlamydia trachomatis salpingitis causes inflammatory damage to the fallopian tube and could potentially cause initiation and progression of high-grade serous ovarian cancer (HGSC). Furthermore, C. trachomatis infection may stimulate mucin 1 (MUC1) protein production, possibly affecting anti-MUC1 antibody levels. The aim of this study was to examine if serology indicating past infection with C. trachomatis as well as anti-MUC1 production was associated with subsequent risk of HGSC. MATERIALS AND METHODS: In a prospective nested case–control study within the Northern Sweden Health and Disease Study and the Northern Sweden Maternity Cohort, the prevalence of chlamydial and anti-MUC1 antibodies was analyzed in blood samples drawn more than one year before diagnosis from 92 women with HGSC and 359 matched controls. Matching factors were age, date at blood draw, and sampling cohort. Plasma C. trachomatis IgG was analyzed using commercial micro-immunofluorescence test; chlamydial Heat Shock Protein 60 IgG (cHSP60) and anti-MUC1 IgG were analyzed with ELISA technique. RESULTS: The prevalence of C. trachomatis IgG and cHSP60 IgG antibodies, as well as the level of anti-MUC1 IgG was similar in women with HGSC and controls (16.3% vs. 17.0%, P = 0.87; 27.2% vs. 28.5%, P = 0.80; median 0.24 vs. 0.25, P = 0.70). Anti-MUC1 IgG and cHSP60 IgG levels were correlated (r = 0.169; P < 0.001). CONCLUSIONS: The findings of this prospective nested case–control study did not support an association between C. trachomatis infection, as measured by chlamydial serology, or anti-MUC1 IgG antibodies, and subsequent risk of HGSC. |
url |
http://www.sciencedirect.com/science/article/pii/S1936523319302992 |
work_keys_str_mv |
AT sarahjonsson chlamydiatrachomatisandantimuc1serologyandsubsequentriskofhighgradeserousovariancancerapopulationbasedcasecontrolstudyinnorthernsweden AT evalundin chlamydiatrachomatisandantimuc1serologyandsubsequentriskofhighgradeserousovariancancerapopulationbasedcasecontrolstudyinnorthernsweden AT fredrikelgh chlamydiatrachomatisandantimuc1serologyandsubsequentriskofhighgradeserousovariancancerapopulationbasedcasecontrolstudyinnorthernsweden AT ulrikaottander chlamydiatrachomatisandantimuc1serologyandsubsequentriskofhighgradeserousovariancancerapopulationbasedcasecontrolstudyinnorthernsweden AT annikaidahl chlamydiatrachomatisandantimuc1serologyandsubsequentriskofhighgradeserousovariancancerapopulationbasedcasecontrolstudyinnorthernsweden |
_version_ |
1724909765598904320 |